"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology-Arlington South conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 12 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 5 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology-Arlington South" #1 sponsor was "Celgene" with 5 trials, followed by "Radiation Therapy Oncology Group" with 5 trials sponsored, "National Cancer Institute (NCI)" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "NSABP Foundation Inc" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology-Arlington South" #1 collaborator was "National Cancer Institute (NCI)" with 9 trials as a collaborator, "NRG Oncology" with 8 trials as a collaborator, "Radiation Therapy Oncology Group" with 2 trials as a collaborator, "Canadian Cancer Trials Group" with 1 trials as a collaborator and "Cancer and Leukemia Group B" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology-Arlington South" are "Breast Cancer" (4 trials), "Lung Cancer" (2 trials), "Non Small Cell Lung Cancer" (2 trials), "Prostate Cancer" (2 trials) and "Stage II Breast Cancer" (2 trials). Many other conditions were trialed in "Texas Oncology-Arlington South" in a lesser frequency.

Most popular intervention types in "Texas Oncology-Arlington South" are "Drug" (18 trials), "Radiation" (11 trials), "Other" (5 trials), "Biological" (4 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Laboratory Biomarker Analysis" (4 trials), "Paclitaxel" (4 trials), "3-Dimensional Conformal Radiation Therapy" (3 trials) and "Carboplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology-Arlington South" are 21 trials for "All" genders, 6 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology-Arlington South". undefined are not yet recruiting, 2 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Texas Oncology-Arlington South, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology-Arlington South, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".